Prescribers reminded about risks of voriconazole

The latest edition of the MHRA's Drug Safety Update highlights the risk of hepatotoxicity, phototoxicity and squamous cell carcinoma associated with the antifungal, voriconazole (Vfend).

Patients may develop squamous cell carcinoma without a prior phototoxic reaction | SCIENCE PHOTO LIBRARY
Patients may develop squamous cell carcinoma without a prior phototoxic reaction | SCIENCE PHOTO LIBRARY

Liver toxicity

A review of trial data showed that some patients taking voriconazole experienced serious hepatic reactions (including hepatitis and fulminant hepatic failure), some of which were fatal. The majority of these reactions occurred in individuals with serious underlying medical conditions. Transient hepatic reactions have occurred in those with no risk factors, although hepatic function usually reverted to normal once voriconazole treatment was stopped.


LFTs (specifically, AST and ALT levels) should be performed before starting treatment, then weekly for the first month and monthly thereafter if no changes are seen in the first month. Voriconazole should be discontinued if AST or ALT levels become markedly elevated; however, consideration must be given to the risk-benefit balance of treatment for the individual patient.

Phototoxicity and squamous cell carcinoma

The MHRA has received 3 Yellow Card reports of skin disorders in patients taking voriconazole in the past 12 months.


The recommendations for healthcare professionals are to:

  • advise all patients, including children, to avoid direct sunlight and use measures such as protective clothing and sufficient sunscreen with a high SPF.
  • consider stopping treatment if phototoxic reactions develop and refer the patient to a dermatologist.
  • if treatment is continued despite a phototoxic reaction, monitor the skin frequently for pre-cancerous lesions and discontinue therapy if pre-cancerous lesions or squamous cell carcinoma develops.

Further resources available

Pfizer is distributing tools (a Q&A brochure, checklist and patient alert card) to assist healthcare professionals in improving monitoring and risk management.

View Vfend drug record

Further information: MHRA Drug Safety Update, May 2014

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more